Author/Authors :
Talei Abdolrasoul نويسنده , Shafa Shariat Panahi Mehdi نويسنده , Akrami Majid نويسنده Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran , Hamedi Sayed Hasan نويسنده Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical Sciences, , Kadkhodaei Behnam نويسنده Department of Pathology,Shiraz University of Medical
Sciences,Shiraz,Iran , Ansari Mansour نويسنده Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran , Zangouri Vahid نويسنده Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran , Ahmadloo Niloofar نويسنده Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran , Mohammadianpanah Mohammad نويسنده Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran , Nasrolahi Hamid نويسنده Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran , Omidvari Shapour نويسنده Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran , Mosalaei Ahmad نويسنده Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract :
Background: Radiotherapy, as an adjuvant treatment, plays a well-known role in
prevention of locoregional recurrence in breast cancer patients. This study aims to
investigate the impact of radiotherapy in patients with N1 disease.
Methods: In this retrospective study, we reviewed the characteristics and treatment
outcomes of 316 patients with a biopsy proven diagnosis of breast carcinoma and 1-3
positive axillary lymph nodes. The patients received treatment between 1995 and 2014.
The patients had a median follow-up of 60 (range: 6-182) months.
Results: This study was conducted on 316 patients with a median age of 48 (range:
26-86) years. Among patients, 215 underwent modified radical mastectomy and 101 had
breast-conserving surgery before adjuvant treatment. Indeed, 259 patients received
radiotherapy (radiation group) and 57 did not (control group). There was locoregional
recurrence in one control group patient and two patients in the radiation group.
Multivariate analysis results indicated hormone receptor status as an independent
prognostic factor for the 5-year disease-free survival rate. Estrogen and progesterone
receptor negativity (HR = 1.80, 95% CI: 1.02-3.19, P=0.043) also had a negative
influence on the 5-year disease-free survival rate. However, radiotherapy had no
significant effect on disease-free survival (P=0.446) and overall survival (P=0.058) rates.
Conclusion: The results showed that adjuvant radiotherapy had no prognostic
impacts on locoregional and distant disease control in breast cancer patients with N1
disease.
